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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Currently, intracerebral hemorrhage (ICH) has the highest mortality rate of all stroke 
subtypes (Counsell et al 1995; Qureshi et al 2005). Hematoma growth is a principal cause of 
early neurological deterioration. Prospective and retrospective studies indicate that up to 38% 
hematoma expansion is noted within three hours of ICH onset and that hematoma volume is an 
important predictor of 30-day mortality (Brott et al 1997; Qureshi et al 2005). This article will 
review current standard of care measures for ICH patients and new research directed at early 
hemostatic therapy and minimally invasive surgery.
Keywords: ICH, hemostatic therapy, recombinant factor VII, surgical management
Intracerebral hemorrhage
An intracerebral hemorrhage (ICH) account for only 15% of all strokes but it is one of 
the most disabling forms of stroke (Counsell et al 1995; Qureshi et al 2005). Greater 
than one third of patients with intracerebral hemorrhage (ICH) will not survive and only 
twenty percent of patients will regain functional independence (Counsell et al 1995). 
This high rate of morbidity and mortality has prompted investigations for new medical 
and surgical therapies for intracerebral hemorrhage.
Primary ICH develops in the absence of any underlying vascular malformation 
or coagulopathy. Primary intracerebral hemorrhage is more common than secondary 
intracerebral hemorrhage. Hypertensive arteriosclerosis and cerebral amyloid angi-
opathy (CAA) are responsible for 80% of primary hemorrhages (Sutherland and Auer 
2006). At times it may be difﬁ  cult to identify the underlying etiology because poorly 
controlled hypertension is often identiﬁ  ed in most ICH patients. Patients with CAA-
related ICH are more likely to be older and the volume of hemorrhage is usually  30 cc 
(Ritter et al 2005). Hypertension related ICH is frequently seen in younger patients, 
involving the basal ganglia, and the volume of blood is usually  30 cc (Lang et al 
2001). However these characteristics are nonspeciﬁ  c and histopathological studies 
are needed to conﬁ  rm a deﬁ  nitive diagnosis of CAA or hypertension related ICH. 
Hypertension causes high pressure within the Circle of Willis resulting in smooth cell 
proliferation followed by smooth muscle cell death. This may explain why hypertension 
related ICH are frequently located deep within the basal ganglia, thalamus (Figure 1), 
cerebellum, pons and rarely the neocortex (Campbell and Toach 1981; Sutherland and 
Auer 2006). In contrast, preferential amyloid deposition within leptomeningeal and 
intraparenchymal cortical vessels may explain the reason for large superﬁ  cial lobar 
hemorrhages with amyloid angiopathy (Auer and Sutherland 2005). It is important 
to identify those afﬂ  icted with cerebral amyloid angiopathy because of the high risk 
of recurrent lobar hemorrhage and predisposition for symptomatic hemorrhage with 
anticoagulants and thrombolytics (Rosand and Greenberg 2000).
Secondary ICH is due to underlying vascular malformation, hemorrhagic conversion 
of an ischemic stroke, coagulopathy, intracranial tumor, etc. Arteriovenous malformations 
and cavernous malformations account for majority of underlying vascular malformations 
(Sutherland and Auer 2006). An AVM (Figure 2) is usually a singular lesion composed Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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of an abnormal direct connection between distal arteries and 
veins. AVMs account for only 2% of all ICH but are associ-
ated with an 18% annual rebleed risk (Al-Shahi and Warlow 
2001). Cavernous malformations are composed of sinusoidal 
vessels and are typically located in within the supratento-
rial white matter. The annual risk of recurrent hemorrhage 
is only 4.5% (Konziolka and Bernstein 1987). Intracranial 
aneurysms usually present with subarachnoid hemorrhage 
but anterior communicating artery and middle cerebral artery 
may also have a parenchymal hemorrhagic component near 
the interhemispheric ﬁ  ssure and perisylvian region respectively 
(Wintermark and Chaalaron 2003). Embolic ischemic strokes 
can often demonstrate hemorrhagic conversion without sig-
niﬁ  cant mass effect (Ott and Zamani 1986). Sinus thrombosis 
should be suspected in patients with signs and symptoms 
suggestive of increased intracranial pressure and radiographic 
evidence of superﬁ  cial cortical or bilateral symmetric hemor-
rhages (Canhoe and Ferro 2005). An underlying cogenial or 
acquired coagulopathy causing platelet or coagulation cascade 
dysfunction can result in ICH. Cogenial disorders account 
for Hemophilia A, Hemophilia B, and other rare diseases. 
Acquired coagulopathy may be attributed to longstanding liver 
disease, renal disease, malignancy, or medication. Particular 
attention has been directed towards oral anticoagulant (OAT) 
associated hemorrhage due to greater risk for hematoma expan-
sion as well as increased 30 day morbidity and mortality rates 
(Flibotte et al 2004; Roquer et al 2005; Toyoda et al 2005; 
Steiner and Rosand 2006). Metastatic tumors account for less 
than ten percent of ICH located near the grey white junction 
with signiﬁ  cant mass effect. The primary malignancy is usu-
ally melanoma, choriocarninoma, renal carcinoma, or thyroid 
carcinoma (Kondziolka and Berstein 1987).
Clinical presentation
The classic presentation of ICH is sudden onset of a focal 
neurological deﬁ  cit that progresses over minutes to hours with 
accompanying headache, nausea, vomiting, decreased con-
sciousness, and elevated blood pressure. Rarely patients pres-
ent with symptoms upon awakening from sleep. Neurologic 
deﬁ  cits are related to the site of parenchymal hemorrhage. 
Thus, ataxia is the initial deﬁ  cit noted in cerebellar hemorrhage, 
whereas weakness may be the initial symptom with a basal 
ganglia hemorrhage. Early progression of neurologic deﬁ  cits 
and decreased level of consciousness can be expected in 50% 
Figure 1 CT scan showing hemorrhage in the left thalamus secondary to hypertension.Vascular Health and Risk Management 2006:2(4) 465–475
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The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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of patients with ICH. The progression of neurological deﬁ  cits 
in many patients with an ICH is frequently due to ongoing 
bleeding and enlargement of the hematoma during the ﬁ  rst 
few hours (Kazui et al 1996; Brott et al 1997; Fujii et al 1998). 
Compared with patients with ischemic stroke, headache and 
vomiting at onset of symptoms is observed three times more 
often in patients with ICH (Gorlick et al 1986; Rathore et al 
2002). Despite the differences in clinical presentation between 
hemorrhagic and ischemic strokes, brain imaging is required 
to deﬁ  nitively diagnose intracerebral hemorrhage.
Diagnosis
Computed tomography (CT) is more widely available so 
CT of the brain has become the initial diagnostic test of 
choice for ICH. However, recent studies suggest MRI and 
CT are equally efﬁ  cacious in diagnosing hyperacute ICH 
(6 hours) (Fiebach et al 2004; Kidwell et al 2004). In 
addition, in 2004, Fiebach and colleagues conducted a mul-
ticenter study and concluded that visual identiﬁ  cation of 
ICH is not difﬁ  cult with MRI with mean sensitivities = 95% 
with expert readers as well as ﬁ  nal-year medical students 
(Fiebach et al 2004). MRI and magnetic resonance angiog-
raphy (MRA) can also help elucidate any underlying cause 
of the hemorrhage. Sometimes the pattern and topography 
of bleeding can give important clues about a secondary 
cause of ICH. For example, subarachnoid blood should raise 
suspicion for a ruptured aneurysm, multiple inferior frontal 
and temporal hemorrhages may be seen after head trauma, 
and ﬂ  uid levels within the hematoma suggest an underly-
ing coagulopathy (Figure 3). Active contrast extravasation 
Figure 2 Axial T2- weighted MR image showing multiple abnormal ﬂ  ow void (arrow) signals indicating presence of an arteriovenous malformation in the left temporal lobe.Vascular Health and Risk Management 2006:2(4) 465–475
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Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
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into the hematoma seen with CT angiography may predict 
hematoma expansion and is predictive of poor outcome 
(Becker et al 1999; Murai et al 1999). Angiography is not 
required for older hypertensive patients with hemorrhages 
in deep subcortical structures with no ﬁ  ndings suggestive 
of an underlying structural lesion. Secondary intracerebral 
hemorrhage should be suspected in patients 45 years of 
age, no risks for hypertensive hemorrhage, presence of 
subarachnoid hemorrhage, prominent vascular structures, 
perisylvian or interhemispheric hemorrhage and angiography 
should be pursued. Angiography should always be considered 
in young non-hypertensive patients with ICH who have no 
obvious explanation for their hemorrhage, or when the only 
risk factor is cocaine or sympathomimetic-drug use (Halpin 
et al 1994; Grifﬁ  ths et al 1997; Zhu et al 1997; Broderick 
and Adams 1999).
Management
Emergency management
ICH is a neurological emergency and initial management 
should be focused on assessing the patients airway, breathing 
capability, blood pressure and signs of increased intracranial 
pressure. The patient should be intubated based on risk of 
aspiration, impending ventilatory failure (PaO2  60 mmHg 
or pCO2  50 mmHg), and signs of increased intracranial 
pressure. (Broderick et al 1999) Emergency measures for 
ICP control are appropriate for stuporous or comatose 
patients, or those who present acutely with clinical signs 
of brainstem herniation. The head should be elevated to 30 
degrees, 1.0–1.5 g/kg of 20% mannitol should be given by 
a rapid infusion, and the patient should be hyperventilated 
to a pCO2 of 30–35 mmHg. (Allen and Ward 1998) These 
measures are designed to lower ICP as quickly as possible 
prior to a deﬁ  nitive neurosurgical procedure (craniotomy, 
ventriculostomy, or placement of an ICP monitor) can be 
done. A number of these patients will present after a fall so 
particular attention should be directed to lacerations, skeletal 
fractures, stabilization of the cervical spine.
Blood pressure
Elevated blood pressure is seen in 46%–56% of patients with 
ICH. (Dandapani et al 1995) It remains unclear if elevated 
blood pressure directly causes hematoma expansion but 
studies have shown elevated systolic, diastolic, and mean 
arterial pressure are associated with a poor outcome in ICH 
(Terrayama et al 1997; Leonardi-Bee et al 2002; Vemmos 
Figure 3 CT scan showing large left parietal lobe lobar hemorrhage with a ﬂ  uid level (arrow) after the patient received r-TPA.Vascular Health and Risk Management 2006:2(4) 465–475
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The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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et al 2004). However, physicians have been reluctant to 
treat hypertension in ICH patients because the fear of 
overaggressive treatment of blood pressure may decrease 
cerebral perfusion pressure and theoretically worsen brain 
injury, particularly in the setting of increased intracranial 
pressure. In 1999, a special group consisting of healthcare 
professionals from the American Heart Association Stroke 
Council addressed these 2 rational theoretical concerns 
while attempting to write guidelines for the management 
of intracerebral hemorrhage. The task force recommended 
maintaining a mean arterial pressure below 130 mmHg in 
patients with a history of hypertension (level of evidence V, 
grade C recommendation). In patients with elevated ICP who 
have an ICP monitor, cerebral perfusion pressure (MAP–ICP) 
should be kept 70 mmHg (level of evidence V, grade C 
recommendation) (Broderick et al 1999).
Early hemostatic therapy
In the past, early neurologic deterioration in ICH was 
attributed to edema and mass effect around the hematoma. 
Pathological, CT, and SPECT studies suggest that continuous 
rebleeding into congested damaged tissue is associated with 
poor clinical outcome and is now an exciting new target of 
treatment (Fisher 1971; Kazui et al 1996; Fujii et al 1998; 
Becker et al 1999; Mayer 2005). Recent interest in hemostatic 
therapy is based on early hematoma growth often seen within 
six hours of onset of ICH in 14%–38% of patients (Kazui 
et al 1996; Brott et al 1997; Fujii et al 1998; Flibotte et al 
2004; Roquer et al 2005). Initial efforts should be directed 
towards identifying thrombolytic, antiplatelet or anticoagu-
lant use and reversing their effects. The biologic half-life of 
recombinant tissue plasminogen activator (rt-PA) at the site 
of the thrombus is limited to 45 minutes and accordingly 
hemorrhagic complications from rt-PA occur within the 
ﬁ  rst few hours of use. Information is scarce to guide recom-
mendations about treatment of hemorrhagic complications 
of thrombolytic therapy (levels of evidence III through V). 
According to guidelines devised by the American Heart 
Association Stroke Council, if bleeding is suspected the fol-
lowing measures should be taken: (1) blood should be drawn 
to measure the patient’s hematocrit, hemoglobin, partial 
thromboplastin time, prothrombin time/INR, platelet count, 
and ﬁ  brinogen (2) blood should be typed and cross-matched 
if transfusions are needed (at least 4 U of packed red blood 
cells, 4–6 U of cryoprecipitate or fresh frozen plasma, and 
1 U of single donor platelets) (Adams et al 1996). These 
therapies should be made available for urgent administration. 
The risk of intracerebral hemorrhage with heparin is related 
to the level of anticoagulation. Heparin can be inactivated 
by 1 mg of protamine sulfate for every 100 IU of heparin 
administered (Wakeﬁ  eld and Stanley 1996). FFP should 
not be used to correct heparin related coagulopathy because 
FFP contains heparin binding antithrombin III (AT-III) 
which may prolong the anticoagulated status (Badjatia and 
Rosand 2005). Warfarin prevents recycling of vitamin K 
and indirectly inhibits synthesis of vitamin K dependent 
coagulation factors. Replenishing vitamin K via the oral or 
intravenous route helps reverse the effect of warfarin but an 
effective response may be delayed over 24 hours. Concomi-
nant use of vitamin K with FFP, cryoprecipitate, or clotting 
factor concentrates are recommended to hasten reversal 
of warfarin induced coagulopathy. Considering the short 
half-life of coagulation factors at least 5–20 mg of vitamin 
K is required to sustain reversal of anticoagulation. Intrave-
nous administration of vitamin K should be limited due to 
concerns of allergic and anaphylactic reactions. In an acute 
setting, vitamin K should not be administered subcutane-
ously because reversal of anticoagulation is neither rapid nor 
reliable (Steiner et al 2006). However, the variable content of 
vitamin K-dependent clotting factors in FFP and the effects 
of dilution have raised concerns that a coagulopathic state 
may persist despite correction of the international normalized 
ratio (INR) (Makris et al 1997). It is not clear at this time 
whether prothrombin complex concentrate is more reliable 
than FFP in repleting coagulation factors but it has proven to 
correct the INR faster than FFP which reduces the incidence 
and extent of hematoma expansion (Fredriksson et al 1992; 
Huttner et al 2006). Use of antiplatelet agents prior to ICH 
is a risk factor for continuous bleeding and poor outcome 
so it is reasonable to treat these patients with platelet infu-
sions and desmopressin (Janssen and van der Meulen 1996; 
Saloheimo et al 2006).
Antiﬁ  brinolytic agents such as e-aminocaproic, tranex-
emic acid, aprotinin, and activated recombinant Factor VII 
(rFVIIa) have been receiving attention for early hemostatic 
therapy in patients with no underlying coagulopathy. How-
ever, rFVIIa is the only agent whose role in treating primary 
ICH has been evaluated in the randomized placebo control 
trial. The Novoseven Phase II trial was an international, 
multicenter, double-blinded trial that clearly demonstrated a 
reduction in early hematoma expansion in patients adminis-
tered rFVIIa within 4 hours of symptom onset compared with 
placebo. In fact, the hemostatic effect was more pronounced 
with incremental doses of rFVIIa (Mayer et al 2005). Despite 
these promising results, early results from the Phase III Fast 
trial showed use of rFVIIa did not alter severe disability or Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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mortality rates at 90 days (Forbes 2007). Complete results 
from the Phase III FAST trial are expected later this year.
Management of ICP
Elevated ICP is deﬁ  ned as intracranial pressure 20 mmHg 
for over 5 minutes. Large volume ICH is commonly 
associated with high ICP and brain tissue shifts related to 
ICP gradients. This problem can be exacerbated by intra-
ventricular hemorrhage, which leads to acute obstructive 
hydrocephalus. The therapeutic goal of treating elevated ICP 
is to maintain ICP  20 mmHg while maintaining cerebral 
perfusion pressure 70 mmHg. When ICP is monitored, 
use of a standard management algorithm results in better 
control, fewer interventions, and shorter duration of therapy. 
Initially, acute and sustained increase in ICP should prompt 
a repeat CT to assess the need for a deﬁ  nitive neurosurgi-
cal procedure. An intravenous sedative such as propofol 
(0.6–6.0 mg/kg/h) or fentanyl (0.5–3.0 µg/kg/h) should be 
given to the agitated patient to attain a motionless state. 
Thereafter, therapy should be directed at controlling blood 
pressure with vasopressors such as dopamine and phenyl-
ephrine if the CPP is  70 mmHg or  with antihypertensive 
agents if the CPP is  70 mmHg. If ICP does not respond to 
sedation and cerebral perfusion management, osmotic agents 
and hyperventilation should be considered (Mckinley et al 
1999). Of the 3 osmotic agents frequently used (mannitol, 
glycerol, and sorbitol), each has characteristic advantages 
and disadvantages. Sorbitol and glycerol are metabolized by 
the liver and interfere with glucose metabolism. However, 
sorbitol is infrequently used due to a short half life and poor 
penetration into the cerebrospinal ﬂ  uid (CSF). Glycerol has 
a half-life less than one hour but it penetrates into the cere-
brospinal ﬂ  uid the best. Mannitol is commonly used because 
it is renally metabolized, has a half-life up to 4 hours, and 
achieves intermediate concentrations within the CSF (Nau 
2000). Large ICH associated with elevated intracranial 
pressure refractory to these measures is fatal in most patients 
but a barbiturate coma may considered as a last resort to 
try to reduce intracranial pressure (Broderick et al 1999; 
Mckinley et al 1999). Corticosteroids are not recommended 
in the management of ICH because they have been proven 
to offer no beneﬁ  t in randomized trials (Tellez and Bauer 
1973; Poungvarin et al 1987).
Ventricular drains should be used in patients with or at risk 
for hydrocephalus. Drainage can be initiated and terminated 
according to clinical performance and ICP values. The volume 
of IVH strongly affects morbidity and mortality at 30-days 
(Tuhrim et al 1988). Preliminary studies with urokinase have 
suggested use of intraventricular thrombolysis within 72 hours 
of IVH may help drain the blood ﬁ  lled ventricles, speed clot 
resolution and decrease 30-day mortality rate (Naff et al 2000; 
Naff et al 2004). Patients are currently being recruited for 
Phase III trials assessing thrombolytic use in intraparenchymal 
and intraventricular hemorrhage.
Anticonvulsant therapy
The 30-day risk of seizures after ICH is about 8%. Seizures 
most commonly occur at the onset of hemorrhage and may 
even be the presenting symptom. Lobar location is an inde-
pendent predictor of early seizures (Passero et al 2003). 
Although, no randomised trial has addressed the efﬁ  cacy of 
prophylactic antiepileptic in ICH patients, the Stroke Council 
of the American Heart Association suggest prophylactic anti-
epileptic treatment may be considered for 1 month in patients 
with intracerebral hemorrhage and discontinued if no seizures 
are noted (Broderick et al 1999; Temkin 2001). Acute man-
agement of seizures entail administering intravenous loraz-
epam (0.05–0.10 mg/kg) followed by an intravenous loading 
dose of phenytoin or fosphenytoin (15–20 mg/kg), valproic 
acid (15–45 mg/kg), or phenobarbital (15–20 mg/kg).
Fever control
Fever after ICH is common and should be treated aggres-
sively because it is independently associated with a poor 
outcome (Schwarcz et al 2001). Sustained fever in excess of 
38.3 °C (101.0 °F) should be treated with acetaminophen and 
cooling blankets. Patients should be physically examined and 
should undergo laboratory testing or imaging to determine the 
source of infection. Fever of neurologic origin is diagnosis 
of exclusion and may be seen when blood extends into the 
subarachnoid or intraventricular (Commichau and Scarmeas 
2003). Intracerebral hemorrhage patients with persistent fever 
that is refractory to acetaminophen and without infectious 
cause may require cooling devices to become normothermic. 
Adhesive surface-cooling systems and endovascular heat-
exchange catheters are better at maintaining normothermia 
than conventional treatment. However, it is still unclear 
whether maintaining normothermia will improve clinical 
outcome (Dringer 2004).
Deep venous thrombosis prophylaxis
Immobilized state due to limb paresis predisposes ICH 
patients for deep vein thrombosis and pulmonary embolism. 
Intermittent pneumatic compression devices and elastic 
stockings should be placed on admission (Lacut et al 2005). 
A small prospective trial by Boeer and colleagues using Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Management of ICH
low-dose heparin on hospital day 2 to prevent thromboebolic 
complications in ICH patients signiﬁ  cantly lowered the inci-
dence of pulmonary embolism and no increase in rebleeding 
was observed (Boeer et al 1991).
Surgical management
Numerous surgical trials since the 1960s offered conﬂ  ict-
ing results and until recently no ﬁ  rm conclusions could be 
reached regarding the operative management of intracere-
bral hemorrhage. In 1995 randomization for the landmark 
Surgical Trial in Intracerebral Hemorrhage (STICH) had 
commenced. This trial was an international, multicenter 
trial that randomized 1033 patients with spontaneous 
supratentorial intracerebral hemorrhage within twenty-
four hours to early surgery or conservative best medical 
therapy. Size, location, and volume of hemorrhage were 
similar in both treatment groups. Patients randomized to 
early surgery had their hematoma evacuated within twenty-
four hours of randomization by the method of choice of 
the designated neurosurgeon. In 77% of cases, craniotomy 
was the surgical procedure and the remainder of cases had 
hematoma removal by burr hole, endoscopy, or stereotaxy 
in similar numbers. Thus, the STICH Trial is primarily a 
trial of craniotomy for ICH removal and left the role of less 
invasive surgery to remove ICH unanswered. Structured 
postal questionnaires were used to assess outcomes with 
the Glasgow Coma Scale, modiﬁ  ed Rankin Scale, Barthel 
index, and mortality at 6-months. Overall, the STICH trial 
revealed no beneﬁ  t from early craniotomy in supratentorial 
intracerebral hemorrhage when compared to initial con-
servative management. Of the prespeciﬁ  ed subgroups that 
were examined, patients with an ICH within a centimeter 
of the cortical surface showed a beneﬁ  t for early surgery. 
However, the statistical testing of this subgroup was not 
adjusted for in the multiple subgroup comparisons in this 
trial. In addition, early surgery was delayed with median 
time from onset to treatment for early surgery group was 
30 hours and that may have affected the outcome (Broderick 
2005; Mendelow et al 2005).
In contrast, infratentorial hemorrhages seem to beneﬁ  t 
from early surgery. Most neurosurgeons believe cerebellar 
hemorrhages greater than 3 centimeters beneﬁ  t from early 
surgical intervention because of the signiﬁ  cant risk of brain-
stem compression and obstructive hydrocephalus within 
24 hours (Ott et al 1974).
New areas of surgical research are focused on combination 
of minimally invasive surgery and and clot lysis with r-tPA 
to remove intracerebral hemorrhage. Small preliminary trials 
have demonstrated that stereotactic aspiration and thromboly-
sis spontaneous intracerebral hemorrhage appears to be safe 
and effective in the reduction of ICH volume (Teernstra et al 
2003; Barrett et al 2005; Vespa et al 2005). The National 
Institute of Health (NIH) has sponsored the Minimally 
Invasive Surgery Plus rtPA for Intracerebral Hemorrhage 
Evacuation (MISTIE) trial to determine the safety of using a 
combination of minimally invasive surgery and clot lysis with 
rt-PA to remove supratentorial primary ICH and compare 
efﬁ  cacy to conventional medical management. The MISTIE 
trial is an open-label randomized treatment trial which is 
currently enrolling patients at multiple centers within the 
United States (NIH 2001).
Conclusion
Currently, no speciﬁ  c therapies improve the outcome after 
ICH. Although rFVIIa limits hematoma expansion, early 
Phase III results failed to show reduction in severe disability 
or mortality rates at 90 days. New trials evaluating the safety 
of the combination of minimally invasive surgery and clot 
lysis with r-tPA to remove intracerebral hemorrhage are 
currently underway.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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